|
|
Feasibility of predicting AML response to induction chemotherapy
|
1R43CA221473-01
|
$299,999
|
$299,999
|
HENDERSON, PAUL
|
ACCELERATED MEDICAL DIAGNOSTICS, LLC
|
|
|
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats
|
5R01CA182284-05
|
$346,525
|
$346,525
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
5R01CA178394-04
|
$346,525
|
$173,263
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
$437,537
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
PI3K Isoform Dependence in Adult Hematopoiesis and Myeloid Leukemia
|
5R01CA196973-02
|
$409,153
|
$409,153
|
GRITSMAN, KIRA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Epigenetic activity of normal and cancer-associated mutant H1 linker histones
|
5F30CA210539-02
|
$44,044
|
$22,022
|
HEALTON, SEAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Mechanisms of Formation and Progression of Preleukemic Stem Cells
|
1R01CA217092-01
|
$397,371
|
$397,371
|
STEIDL, ULRICH
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Role of a Novel Homeobox Transcription Factor (HLX) in Acute Myeloid Leukemia
|
5R01CA166429-06
|
$384,342
|
$384,342
|
STEIDL, ULRICH
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Assay Development for NSD1 Methyltransferase Inhibitor Discovery
|
5R01CA191077-03
|
$312,244
|
$312,244
|
KOLB, EDWARD
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
|
AML-MutationCounter, a tool to detect residual and recurrent leukemia
|
1R41CA213690-01
|
$220,087
|
$220,087
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
|
|
Genetic Analysis of Myeloproliferative Disease
|
3R01CA076167-14S1
|
$24,361
|
$24,361
|
COWELL, JOHN
|
AUGUSTA UNIVERSITY
|
|
|
Genetic Analysis of Myeloproliferative Disease
|
5R01CA076167-14
|
$307,800
|
$307,800
|
COWELL, JOHN
|
AUGUSTA UNIVERSITY
|
|
|
Role of heat shock factors (Hsfs) in tumorigenesis
|
5R01CA132640-16
|
$270,000
|
$270,000
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
|
|
Proteogenomic Translational Research Center for Clinical Proteomic
|
1U01CA214116-01
|
$1,374,609
|
$1,374,609
|
RODLAND, KARIN
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
|
|
A Mouse Model of DNMT3A-Associated Hematologic Malignancy
|
5R01CA183252-04
|
$533,845
|
$533,845
|
GOODELL, MARGARET
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
|
5R01CA164024-05
|
$319,474
|
$319,474
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Mechanisms of KLF4 suppression in pediatric leukemia
|
1R01CA207086-01A1
|
$326,540
|
$326,540
|
LACORAZZA, DANIEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Metabolic Regulation in Leukemia-Initatiating Cells
|
5R01CA193235-03
|
$462,191
|
$462,191
|
NAKADA, DAISUKE
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S1
|
$118,333
|
$9,467
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S2
|
$118,875
|
$9,510
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S3
|
$122,250
|
$9,780
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S4
|
$250,002
|
$20,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-11
|
$3,253,119
|
$260,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
DEFINING THE ROLE OF DOT1L IN DNMT3A-MUTANT LEUKEMIA
|
1K08CA201611-01A1
|
$162,148
|
$162,148
|
RAU, RACHEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Using Stat3 Signaling Profiles to Understand Chemotherapy Resistance in AML
|
5R01CA175026-04
|
$379,294
|
$379,294
|
REDELL, MICHELE
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia
|
4R00CA197498-04
|
$249,000
|
$249,000
|
CHEN, CHUN-WEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Impact of aging on the outcomes of a mouse model of chronic myeloid leukemia
|
5UH2CA213385-02
|
$49,295
|
$49,295
|
CHEN, WENYONG
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection
|
5R01CA181045-04
|
$710,976
|
$710,976
|
DIAMOND, DON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
City of Hope Lymphoma SPORE
|
3P50CA107399-10S1
|
$300,000
|
$30,000
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Image-guided irradiation safely intensifies HSCT regimen for refractory leukemia
|
5R01CA195519-02
|
$272,213
|
$272,213
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia
|
1R01CA213131-01
|
$428,441
|
$428,441
|
KORTYLEWSKI, MARCIN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Targeting microRNAs to eradicate leukemia stem cells
|
1R01CA205247-01A1
|
$434,503
|
$434,503
|
KUO, YA-HUEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
HDAC8 Mediated Regulation of Acute Myeloid Leukemia Pathogenesis and Maintenance
|
5R01CA178387-04
|
$317,475
|
$317,475
|
KUO, YA-HUEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Research career advancement: Role of the SIRT1 deacetylase in maintenance of FLT3
|
5R00CA184411-05
|
$248,999
|
$248,999
|
LI, LING
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics
|
1R01CA213138-01
|
$395,738
|
$134,551
|
M?SCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Targeted activation of autoimmune checkpoints in B cell malignancies
|
7R01CA157644-08
|
$410,875
|
$410,875
|
M?SCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Metabolic basis of B cell lineage leukemia relapse
|
7R35CA197628-02
|
$1,036,898
|
$1,036,898
|
M?SCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Pharmacological modulation of epigenetic changes in AML
|
5R01CA102031-12
|
$342,107
|
$342,107
|
MARCUCCI, GUIDO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Biologic and Therapeutic Significance of miR-155 in AML
|
5R01CA201184-02
|
$554,107
|
$554,107
|
MARCUCCI, GUIDO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Optimizing Busulfan: Efficacy Toxicity and Pharmacometabolomics
|
5R01CA182963-05
|
$515,038
|
$515,038
|
MCCUNE, JEANNINE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-34S1
|
$73,297
|
$19,790
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-34S2
|
$124,999
|
$33,750
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
5P30CA033572-34
|
$2,446,682
|
$660,604
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
|
5R01CA201496-02
|
$463,530
|
$463,530
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Targeting the ARHGAP25 pathway in acute myelogenous leukemia stem cells
|
1K08CA201591-01A1
|
$169,560
|
$169,560
|
WANG, LEO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Personalized vaccine for patients with AML
|
1R01CA212649-01
|
$739,429
|
$739,429
|
AVIGAN, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Determining the role of DNMT-interacting RNAs in myeloid disorders
|
4R00CA188595-03
|
$249,000
|
$249,000
|
DI RUSCIO, ANNALISA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Regulatory role of long noncoding RNAs in normal and cancer cells
|
1R50CA211304-01A1
|
$261,280
|
$261,280
|
EBRALIDZE, ALEXANDER
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Targeting PML for Leukemia Therapy
|
5R01CA142874-07
|
$465,791
|
$465,791
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Targeting Tumor Suppressive Pathways for Cancer Therapy
|
5R35CA197529-03
|
$1,044,000
|
$522,000
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Total relevant funding to Leukemia for this search: $250,547,507
|
